Overview
- Regulators have approved an oral formulation of semaglutide and a recent meta‑analysis found tirzepatide yields larger average weight loss than semaglutide, a combination likely to broaden who takes these drugs and how they are prescribed.
- Real‑world evidence shows wide individual variability: roughly 10 to 30 percent of patients are 'non‑responders' who lose less than 5 percent of body weight at six months and many stop treatment within the first year.
- Clinicians and health leaders are calling for a shift from episodic prescriptions to a chronic, multidisciplinary care model because stopping therapy usually leads to rapid weight regain and current systems lack capacity and equitable access.
- Microdosing, telehealth prescribing, compounding and illicit sourcing are increasingly common but unstudied practices that raise safety and quality concerns given known gastrointestinal side effects, reports of muscle loss, and reports of serious but rarer harms.
- Early observational signals suggest wider effects—an NIH All of Us analysis linked GLP‑1 use to lower odds of multiple substance use disorders and conference data suggest possible male fertility benefits—but researchers stress randomized trials are needed before changing clinical practice.